Artificial β-cell: Clinical experience toward an implantable closed-loop insulin delivery system

Diabetes and Metabolism

Volumn 32, Issue 5 C2, 2006, Pages 497-502

  Renard, E ^a   Costalat, G ^a   Chevassus, H ^b   Bringer, J ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Algorithm; Artificial pancreas; Glucose control; Glucose sensor; Review; Type 1 diabetes mellitus

Indexed keywords

INSULIN; LONG TERM GLUCOSE SENSOR; LONG-TERM SENSOR SYSTEM;

ACCURACY; ALGORITHM; ARTIFICIAL BETA CELL; BIOSENSOR; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; HEART RIGHT ATRIUM; HUMAN; IMPLANT; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; DIABETES MELLITUS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; PANCREAS, ARTIFICIAL; PROSTHESES AND IMPLANTS; REPRODUCIBILITY OF RESULTS;

EID: 33751506973     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(06)72802-6     Document Type: Review

References (33)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
3. Albisser AM, Leibel BS, Ewart TF, et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974;23:297-404.
4. Mirouze J, Selam JL, Pham TC, et al. Evaluation of exogenous insulin homeostasis by the artificial pancreas in insulin-dependent diabetes. Diabetologia 1977;13:273-8.
5. Jaremko J, Rorstad O. Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 1998;21:444-50.
6. Renard E. Implantable closed loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol 2002;2:708-16.
7. Clemens AH, Chang PH, Myers MW. The development of BIOSTATOR, a glucose controlled insulin infusion system (GCIIS). Horm Metab Res 1977;Suppl 8:23-33.
8. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004;56:125-44.
9. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetic Med 2006;23:1-12.
10. Shichiri M, Kawamori R, Yamasaki Y, et al.. Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet 1982;2:1129-31.
11. Shimoda S, Nishida K, Sakakida M, et al. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol Eng 1997;8:197-211.
12. Shichiri M, Sakakida M, Nishida K, et al. Enhanced, simplified glucose sensors: long-term clinical application of a wearable artificial endocrine pancreas. Artif Organs 1998;2:32-42.
13. Schaller HC, Schaupp L, Bodenlenz M, et al. Avoidance of hypo- and hyperglycemia with a control loop system in type 1 DM under daily life conditions. Diabetes Metab 2003;29 (suppl 1):A225 [Abstract].
14. Freckmann G, Kalatz B, Pfeiffer B, et al. Recent advances in continuous glucose monitoring. Exp Clin Endocr Diab 2001;109:S347-S357.
15. Galley P, Wagner R, Buck H, et al. Use of subcutaneous glucose measurements to drive real-time algorithm-directed insulin infusion recommendations. Diabetes Technol Ther 2004;6:245-6.
16. Steil GM, Rebrin K, Hariri F, et al. Continuous automated insulin delivery based on subcutaneous glucose sensing and an external insulin pump. Diabetes 2004;53 (suppl 2):A2 [Abstract].
17. Renard E. Implantable glucose sensors for diabetes monitoring. Min Invas Ther & Allied Technol 2004;13:78-86.
18. Renard E, Costalat G, Bringer J. De la pompe externe à la pompe implantable, la fermeture de la boucle est-elle possible? Diabetes Metab 2002;28 (part 2):2S19-2S25.
19. Renard E, Panteleon AE, Kolopp M, et al. Efficacy of closed-loop control of blood glucose and characterization of delays based on an implantable IV sensor and intraperitoneal insulin pump. Diabetologia 2004;47 (suppl 1):A92 [Abstract].
20. Nelson JA, Stephen R, Landau ST, et al. Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized, unrestrained swine. Metabolism 1982;31:969-72.
21. Point Study Group. One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Lancet 1988;i:864-9.
22. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med 1989;321:574-9.
23. Selam JL, Micossi P, Dunn FL, et al. Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care 1992;15:877-85.
24. Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: A multicenter study. Diabetes Care 1995;18:388-92.
25. Gin H, Renard E, Melki V, et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab 2003;29:602-7.
26. Renard E, Bouteleau S, Jacques-Apostol D, et al. Insulin underdelivery from implanted pumps using peritoneal route: determinant role of insulin-pump compatibility. Diabetes Care 1996;19:812-7.
27. Broussolle C, Jeandidier N, Hanaire-Broutin H for The Evadiac Study Group. French multicentre experience with implantable insulin pumps. Lancet 1994;343:514-5.
28. 1c between implantable insulin pumps using U400 HOE 21Ph insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab 2002;28:133-7.
29. Renard E, Shah R, Miller M, et al. Accuracy of real-time blood glucose measurement by long-term sensor system allows automated insulin delivery in diabetic patients. Diabetes 2002;51 (suppl 2):A126 [Abstract].
30. Renard E, Shah R, Miller M, et al. Sustained safety and accuracy of central IV glucose sensors connected to implanted insulin pumps and short-term closed-loop trials in diabetic patients. Diabetes 2003;52 (suppl 2):A36 [Abstract].
31. Olsen CL, Chan E, Turner DS, et al. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 1994;17:169-76.
32. Sodoyez JC, Koch M, Sodoyez-Goffaux F. Anticorps anti-insuline: méthodologie et implications cliniques. Diabetes Metab 1991;17:255-69.
33. Renard E, Apostol D, Lauton D, et al. Quality of life in diabetic patients treated by insulin pumps. QoL Newsletter 2002;28:11-3.